On Friday 7 May, the European Commission opened a public feedback on its draft revision of the legislation on medicines for rare diseases (141/2000) and on medicines for children (1901/2006): this revision was one of the major promises made by the Commission in its pharmaceutical strategy and will be its main initiative regarding unmet therapeutic needs (see EUROPE B12710A9).
The aim of the draft revision, expected in the first quarter of 2022, will be to encourage research and development...